Delivering our partners preclinical discoveries through world class capabilities,
directed by teams with a reputation for collaboration and scientific excellence
Insights from target to IND
Cutting-edge synthetic technology and expertise in special chemical matters have been centralized to form a variety of special chemistry platforms.
Magical Power of QM
To Empower Organic Syntheses
With powerful workstations, state of the art software, and our expertise on reaction QM analyses, real-time incorporations of such calculations in prospective analyses become routines in Research Service Division.
A Diverse New Modality That Unlocks New Target Classes
Bifuctional molecules are opening up once-inaccessible targets and enabling development of drugs that are less susceptible to target protein mutations.
Tumor Evolution Selectively Inactivates the Core Microrna Machinery for Immune Evasion
Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and coculture system.
Enabling Technology for Targeted Protein Degradation
Identification and characterization of new bifunctional molecules including degraders using synergistic power of fragment and DEL screening, biophysics and structural biology
Opportunities and Challenges for Treatments Delivered by Adeno-Associated Viruses
The word “rare” in the term rare disease can be confusing to the uninitiated. About 300 million people worldwide are living with one or more of over 6,000 rare diseases. This is just under 4% of the world population. So it’s not actually rare to have a rare disease.